期刊文献+

放射性粒子^(125)I对胶质瘤细胞治疗作用的实验研究 被引量:4

Therapeutic effect of ^(125)I in treatment of nude mice implanted with human glioma
下载PDF
导出
摘要 目的探讨放射性粒子125I在动物体内抗人脑胶质瘤的效果及其作用机制。方法建立人胶质瘤的动物模型,瘤内植入放射性粒子125I,观察肿瘤生长情况,在电镜下观察其超微结构的变化,采用TUNEL技术检测肿瘤组织的凋亡情况,流式细胞仪检测Bax/Bcl-2的表达,并应用免疫组化染色检测血管密度和VEGF、bFGF的表达。结果成功建立了人胶质瘤细胞U251的动物模型,植入放射性粒子125I后,胶质瘤生长较对照组明显受到抑制(P<0.05,P<0.01),电镜下可呈现核断裂、染色质边聚等细胞凋亡的形态特征。检测显示:和对照组相比,肿瘤组织的Bax/Bcl-2(1.88±0.47vs1.11±0.52,P<0.01)和组织凋亡率的IHS评分(3.64±0.89vs0.81±0.45,P<0.01)明显增高;肿瘤组织的微血管密度IHS评分(1.40±0.55vs3.23±0.87,P<0.01)、VEGF的IHS评分(1.58±0.55vs4.19±0.45,P<0.01)和bFGF的IHS评分(2.44±0.89vs3.52±0.79,P<0.05)明显降低。结论放射性粒子125I对在体人胶质瘤U251有明确的抑制作用,促进瘤细胞凋亡和降低瘤组织微血管密度可能是其主要作用机制。 Objective To investigate the efficacy of 125I in treatment of nude mice implanted with human glioma cell line U251 and the related mechanism. Methods The animal models of human malignant glioma were established with nude mice. 125I was implanted into tumors and the tumor growth was observed. The ultrastructural change was observed by electron microscopy. The apoptosis of the tumor tissue was examined by in situ end -labelling technique; expression of Bax/Bcl -2 was detected by flow cytometer. Blood vessel density and expression of VEGF,bFGF were observed by immunohistochemistry. Results Nude mouse models of human malignant glioma were successfully established. Compared with control group,125I significantly inhibited tumor growth in nude mice( P 〈 0. 05,P 〈 0. 01 ). Electron microscopy demonstrated that the tumor cells displayed apoptosis characteristics such as nuclear fragmentation,margination of condensed chromatin. The expression of Bax/Bcl-2 in the 125I implanting group ( 1.88 ± 0. 47) was significantly increased compared with that in the control group ( 1. 11 ± 0. 52,P 〈 0. 01) ,and the apoptosis rate of tumor tissues in the 125 I implanting group ( 3. 64 ± 0. 89) was significantly higher ( 0. 81 ± 0. 45,P 〈 0. 01). The blood vessel density in the 125 I implanting group was significantly lower than that in the control group ( 1. 40 ± 0. 55 vs 3. 23 ± 0. 87,P 〈 0. 01). The expression of VEGF,bFGF in 125 I implanting group was significantly lower than that in the control group ( 1. 58 ± 0. 55 vs 4. 19 ± 0. 45 for VEGF,P 〈 0. 01; 2. 44 ± 0. 89 vs 3. 52 ± 0. 79 for bFGF,P 〈 0. 05). Conclusion 125 I has prominent inhibitory effect against human gliomas,and the main mechanism might be the promotion of apoptosis and decrease of blood vessel density.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2010年第1期46-50,共5页 Academic Journal of Second Military Medical University
基金 河北省自然科学基金(C2004000671)~~
关键词 胶质瘤 间质内放疗 放射性核素125I 动物模型 细胞凋亡 微血管密度 glioma brachytherapy radioisotope 125I animal model apoptosis microvessel density
  • 相关文献

参考文献6

二级参考文献33

  • 1吴在德 郑树 吴承远 等编.高等教育教材.外科学.第5版[M].北京:人民卫生出版社,2000.306. 被引量:2
  • 2Sneed P, Mcdermott MW,Gutin P,etal. Interstitial brachytherapy procedures for brain tumors. Seminars in Surgical Oncology,1997,13:157-166. 被引量:1
  • 3Gaspar LE,Zamorano, LJ,Shamsa F,et al. Permanent125Iodine implants for recurrentmalignant gliomas. Int J Radait Oncol Bio Phys, 1999,43:977-982. 被引量:1
  • 4Halligan JB, Stelzer KJ, Rostomily RC et al. Operation and permanent lowactivity125I brachytherapy for recurrent high-grade astrocytomas.Int J Radait Oncol BioPhys,1996,35:541-547. 被引量:1
  • 5Vikram B. Permanent Iodine-125 boost after teletherapy in primary cancer of thenasopharynx is safe and highly effective :long-term results. Int J Radait oncol Bio Phys,1997,38:1140. 被引量:1
  • 6Matsumoto S, akeda M, Shibuya H, et a1. T1 and T2 squamous cell carcinomas of thefloor of the mouth: Results of brachytherapy mainly using198 Au grains. Int J Radait OncolBio Phys, 1996,34:833-841. 被引量:1
  • 7Chen A, Galloway M, Landreneau R, et al. Introperative 125 I brachytherap forhigh-risk stage I non-small cell lung carcinoma. Int J Radait Oncol Bio Phys,1999,44:1057-1063. 被引量:1
  • 8Peterz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma ofthe pancreas with I-125 implantation. Int J Radait Oncol Bio Phys, 1989,17:931-935. 被引量:1
  • 9Martinez-Monge R,Nag S,Edward W,et al125 I brachytherapy for colorectaladenocarcinona recurrent in the pelvia and paraortics. Int J Radait oncol BioPhya,1998,42:545-500. 被引量:1
  • 10Storey MR,Landgren RC,Cottone JL, et al.Transperineal 12J Iodine im-plantation fortreatment of clinically localized prostate cancer:5-year tumor control and morbidity. IntJ Radait Oncol Bio Phys, 1999,43:565-570. 被引量:1

共引文献217

同被引文献29

  • 1肖争,王学峰,晏勇,栾国明,阎丽.难治性癫癇患者脑组织中5种耐药基因产物的同步表达及临床意义[J].中华神经科杂志,2004,37(6):500-503. 被引量:17
  • 2Racine RJ. Modification of seizure activity by electrical stimulation : Cortical areas [ J ]. Electroencephalogr Clin Neurophysiol, 1975,38 ( 1 ) : 1 - 12. 被引量:1
  • 3Liu B ,Wang T,Wang L,et al. Up - regulation of major vault protein in the frontal cortex of patients with intractable frontal lobe epilepsy [ J 1. J Neurol Sci,2011,308( 1 -2) :88 -93. 被引量:1
  • 4Aronica E, Gorter JA, van Vliet EA, et al. Overexpression of the human major vault protein in gangliogliomas [ J ]. Epilepsia, 2003,44 ( 9 ): 1166 - 1175. 被引量:1
  • 5Guo Z,Zhu J, Zhao L, et al. Expression and clinical significance of multidrug resistance proteins in brain tumors [ J ]. J Exp Clin Cancer Res , 2010,29 : 122. 被引量:1
  • 6Sisodiya SM, Martinian L, Scheffert GL, et al. Vascular colocalization of P - glycoprotein, multidrug - resistance associated proteinl, breast eance resistance protein and major vault protein in human epileptogenic pathologies. Neuropathology and applied [ J ]. Neurobiology, 2009,32 (1) :51 -63. 被引量:1
  • 7Van Vliet EA, Aronica E, Redeker S, et al. Expression and cellular distribution of major vault protein : A putative marker for pharmacoresis- tance in a rat model for temporal lobe epilepsy[J]. Epilepsia ,2004,45 (12) :1506 -1516. 被引量:1
  • 8Luna - Tortos C, Fedrowitz M, Loscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistance - associated proteins ( MRP1,2 and 5 ) that are overexpressed in pharmacoresistant epilepsy[ J]. Neuropharmacology,2010,58 (7) : 1019 - 1032. 被引量:1
  • 9Labbozzetta M, Notarbartolo M, Poma P, et al. Curcumin as a possible lead compound against hormone - independent, muhidrug - resistant breast cancer[J] .Ann N Y Acad Sci,2009,1155:278 -283. 被引量:1
  • 10Cavaliere R, Wen PY,Schiff D. Novel therapies for malig-nant gliomas[]]. Neurol Clin,2007,25(4) :1141 -1171. 被引量:1

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部